Amgen Files Proxy Statement for Shareholder Meeting

TL;DR

Amgen's proxy statement is out - time to vote on directors and exec pay.

AI Summary

Amgen Inc. filed a Definitive Proxy Statement (DEFA14A) on April 26, 2024, for its annual shareholder meeting. The filing outlines the company's governance, executive compensation, and proposals to be voted on by shareholders. Key items likely include the election of directors and ratification of independent auditors.

Why It Matters

This filing provides shareholders with crucial information to make informed voting decisions on company leadership and corporate governance matters.

Risk Assessment

Risk Level: low — This is a standard regulatory filing (DEFA14A) for an annual shareholder meeting, not indicating any unusual risks.

Key Players & Entities

• AMGEN INC (company) — Registrant
• 0001193125-24-117972 (filing_id) — Accession Number
• 20240426 (date) — Filing Date
• ONE AMGEN CENTER DRIVE (address) — Principal Business Address
• THOUSAND OAKS (city) — Principal Business Address City
• CA (state) — Principal Business Address State
• 91320 (zip_code) — Principal Business Address Zip

FAQ

From the Filing

0001193125-24-117972.txt : 20240426 0001193125-24-117972.hdr.sgml : 20240426 20240426160552 ACCESSION NUMBER: 0001193125-24-117972 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20240426 DATE AS OF CHANGE: 20240426 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMGEN INC CENTRAL INDEX KEY: 0000318154 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 953540776 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-37702 FILM NUMBER: 24883577 BUSINESS ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 BUSINESS PHONE: (805)447-1000 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 FORMER COMPANY: FORMER CONFORMED NAME: AMGEN DATE OF NAME CHANGE: 19870305 DEFA14A 1 d771981ddefa14a.htm DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☑  Filed by the registrant      ☐  Filed by a party other than the registrant Check the appropriate box:     ☐      Preliminary Proxy Statement ☐   CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14A-6(E)(2)) ☐   Definitive Proxy Statement ☑   Definitive Additional Materials ☐   Soliciting Material Pursuant to Section 240.14a-12 AMGEN INC. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of filing fee (check the appropriate box):     ☑      No fee required. ☐   Fee paid previously with preliminary materials. ☐   Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0- 11. Subsequent to this filing, Amgen Inc. sent the following summary communication to one or more investors and/or proxy advisory firms for their consideration in making their vote recommendations.   Amgen 2024 Proxy Statement Key Highlights 2023 was another year of strong execution of our strategy . We acquired Horizon Therapeutics plc (Horizon), advanced our innovative pipeline, and delivered strong performance. Execution of Our Strategy The core of Amgen’s strategy is innovation. More specifically, we seek to provide first- or-best-in-class medicines that make a significant difference for patients suffering from serious diseases. Some of these innovative medicines are developed internally and some are sourced externally. · In 2023, we acquired Horizon , a leading provider of innovative medicines to treat rare inflammatory diseases. The medicines we acquired are all very early in their lifecycles and, by leveraging Amgen’s world-class biologics capabilities, decades of experience in inflammation, and extensive global presence, we believe they have significant growth potential. · Today, our portfolio spans four therapeutic areas: General Medicine ; Oncology ; Inflammation ; and, now, Rare Disease . In each area, we have numerous well-established products currently on the market, promising new innovative medicines advancing through our pipeline, and biosimilars. – In our Oncology pipeline, Amgen was granted three Breakthrough Therapy Designations 1 by the U.S. Food and Drug Administration, or FDA, last year for tarlatamab in small cell lung cancer, BLINCYTO ® in acute lymphoblastic leukemia, and LUMAKRAS ® in combination with Vectibix ® in colorectal cancer. – In General Medicine , a number of our medicines delivered record 2023 sales, including our cholesterol treatment Repatha ® and our osteoporosis medicines Prolia ® and EVENITY ® .